

USC Norris Comprehensive Cancer Center

Keck Medicine of USC



BLOOD AND MARROW TRANSPLANT AND CELL THERAPY PROGRAM

The **USC Norris Blood and Marrow Transplant and Cell Therapy Program**, a part of the USC Norris Comprehensive Cancer Center, is one of the leading providers for hematologic malignancy and stem cell transplant medicine in Southern California.

One of the top transplant centers in the country, our program has reached a historic high for survival rates. While the national average for the one-year survival rate of adult allogeneic bone marrow transplants is 76.5%, the rate for USC Norris patients is 89.2%*. This survival rate is among the highest in the nation and follows many years of the program presenting a one-year survival rate of 80% to 88%.

We offer a personalized approach to autologous and allogeneic bone marrow and peripheral blood stem cell transplants for blood cancers, as well as cellular therapies including **chimeric antigen receptor (CAR) T cell products**.

The results of CAR T cell therapy for treating lymphoma and other cancers are highly promising and exciting. The CAR T cell program at USC Norris Cancer Hospital, led by Preet M. Chaudhary, MD, PhD, employs a multi-disciplinary team approach to patient care. Three CAR T cell therapies are currently available at USC Norris Cancer Hospital — **axicabtagene ciloleucel (Yescarta)**, **brexucabtagene autoleucel (Tecartus)** and **Ciltacabtagene autoleucel (CARVYKTI)**.

USC Norris has a skilled complement of physicians ready to support our community with this personalized approach to cancer management.

* according to the 2023 Center for International Blood and Marrow Transplant Research report

COORDINATED, PERSONALIZED CARE THAT BENEFITS YOUR PATIENTS

The USC Norris BMT program is integrated and coordinated through the collective efforts of a multidisciplinary team and has developed a quality management plan that includes:

- BMT laboratory
- Collection facility (apheresis and bone marrow)
- Blood bank
- Nursing (inpatient/outpatient)

to collaboratively identify opportunities to improve care and outcomes.

To refer a patient, please contact our BMT/CAR T cell intake specialist:

Stephanie Rupit Venegas

stephanie.rupit-venegas@med.usc.edu

Phone

(323) 865-3741

Fax

(323) 865-3021

BLOOD AND MARROW TRANSPLANT AND CELL THERAPY PROGRAM

AVAILABLE CAR-T CELL THERAPIES

Axicabtagene ciloleucel (Yescarta) has been approved by the FDA to treat adults with follicular lymphoma and large B-cell non-Hodgkin lymphomas whose cancer has not been fully successfully treated with at least two prior treatment regimens. Over 70% of patients who received axicabtagene ciloleucel experienced either a complete or partial response (according to Kite Pharma).

Brexucabtagene autoleucel (Tecartus) is an option when a patient's mantle cell lymphoma resists or returns after their first treatment and is now an option for patients with acute lymphoblastic leukemia. Brexucabtagene autoleucel helped more than 60% of patients achieve complete or partial remission (according to Kite Pharma).

Ciltacabtagene autoleucel (CARVYKTI) has been approved for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy. Ciltacel led to a response in 98% of patients (according to Janssen Pharmaceuticals).

To refer a patient, please contact our BMT/CAR T cell intake specialist:

Stephanie Rupit Venegas
stephanie.rupit-venegas@med.usc.edu

Phone

(323) 865-3741

Fax

(323) 865-3021

KeckMedicine.org/cancer


OUR EXPERT MEDICAL TEAM



Ann Mohrbacher, MD
Associate Professor of
Clinical Medicine, Keck
School of Medicine of USC




Preet Chaudhary, MD, PhD
Chief, Jane Anne Nohl Division
of Hematology and Center for
the Study of Blood Diseases,
Keck School of Medicine of USC




**Eduardo Fernandez
Hernandez, MD**
Assistant Professor of
Clinical Medicine, Keck
School of Medicine of USC



Kevin Kelly, MD, PhD
Associate Professor of
Clinical Medicine, Keck
School of Medicine of USC



Eric Tam, MD
Assistant Professor of
Clinical Medicine, Keck
School of Medicine of USC



Karrune Woan, MD
Assistant Professor of
Clinical Medicine, Keck
School of Medicine of USC



George Yaghmour, MD
Assistant Professor of
Clinical Medicine, Keck
School of Medicine of USC



**USC Norris Comprehensive
Cancer Center**

Keck Medicine of USC

**USC Norris Blood and Marrow
Transplant and Cell Therapy Program**

1441 Eastlake Ave., Los Angeles, CA 90033

Keck Medical Center is proud to be ranked
as a top hospital by US News & World Report